Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: A Wisconsin oncology network study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 379-384

  Chang, Julie ^a   Seo, Songwong ^a   Kim, Kyungmann ^a   Werndli, Jae ^b   Bottner, Wayne ^c   Rodrigues, Gilberto ^d   Sanchez, Federico ^d   Saphner, Thomas ^e   Longo, Walter ^a   Kahl, Brad ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^d ProHealth Care Regional Cancer Center   (United States)

^e St Vincent Regional Cancer Center CCOP   (United States)

Author keywords

DLBCL; Granulocyte macrophage colony stimulating factor; Sargramostim; Toxicity

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; AGED; AGING; ANOREXIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DRUG TOLERABILITY; DYSPNEA; EPIGASTRIC PAIN; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; INJECTION SITE REACTION; INTERNATIONAL PROGNOSTIC INDEX; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LEUKOPENIA; MALE; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STROKE; SURVIVAL RATE; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG POTENTIATION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG SYNERGISM; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952310253     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.071     Document Type: Article

References (30)

1. Friedberg JW, Fisher RI. Large-cell lymphoma. In: Canellos GP, Lister TA, Young B, eds. The Lymphomas. 2nd ed. Philadelphia, PA: Elsevier Inc.; 2006:295-303.
2. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-7. (Pubitemid 46638950)
3. Morrison VA, Weller EA, Habermann TM, et al. Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494/C9793 update. J Clin Oncol, 2007; 25 (18 suppl): 443s (abstract 8011).
4. Coiffier B, Lepage E, Brire J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346:235-42. (Pubitemid 34438862)
5. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-26. (Pubitemid 46211317)
6. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-16.
7. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-6. (Pubitemid 23095683)
8. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916-23. (Pubitemid 46854426)
9. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997; 8:973-8.
10. Zinzani PL, Pavone E. Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 11:3974-9. (Pubitemid 27220941)
11. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2:47-56. (Pubitemid 32677850)
12. Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008; 26:2725-31.
13. Venugopal P, Sivaraman S, Huang X, et al. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines. Blood 1998; 92(suppl 1):247a (abstract 1009).
14. Venugopal P, Sivaraman S, Huang X-K, et al. Cytokines enhance rituximab-binding to tumor cells. Blood 2000; 96(suppl 1):131a (abstract 564).
15. Sivaraman S, Deshpande CG, Kunkel L, et al. Rituxan® induced apoptosis in DHL-4 cells: effect of IL-4 and GM-CSF. Blood 1999; 94(suppl 1):254b (abstract 4344).
16. Deshpande CG, Sivaraman S, Connor T, et al. Effect of GM-CSF and/or IL-2 on Rituxan® induced cellular apoptosis on DHL-4 cells. Blood 1999; 94(suppl 1):245b (abstract 4304).
17. Every JJ, Lonial S. Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumor activity. Expert Opin Biol Ther 2005; 5:293-311. (Pubitemid 40516741)
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-53. (Pubitemid 29162950)
19. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-94.
20. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has high-riskdisease? Blood 1994; 83:1165-73.
21. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4:295-305. (Pubitemid 16133082)
22. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27-34. (Pubitemid 28041575)
23. Mainwaring PN, Cunningham D, Gregory W, et al. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patient older than 60 with high grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO vs. PMitCEBO. Blood 2001; 97:2991-7.
24. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13:2530-9.
25. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33-8. (Pubitemid 29300131)
26. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42. (Pubitemid 39434941)
27. Treon SP, Shima Y, Raje N, et al. Interferon-γ induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells. Blood 1999; 94(suppl 1):119a (abstract 521).
28. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33. (Pubitemid 28363048)
29. Sparano JA, Negassa A, Lansigan E, et al. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. Med Oncol 2005; 22:257-67. (Pubitemid 41176322)
30. Haq R, Sawka CA, Franssen E, et al. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35:527-36 (Pubitemid 30015652)